MXC: $0.059
We develop

MGC’s collaboration with RMIT has led to two major projects in the field of data collection, a crucial element for MGC’s clinical program and for the Phytocannabinoid industry as a whole, where there is a significant dearth of knowledge and data, responsibly collected and maintained, to be used for future product development, health and safety studies, and much more.

CannEpil® APP

The ‘CannEpil®’ app is intended to be used by person (or the guardian of the person) taking CannEpil® as a prescription treatment.

This App is a cross platform application available to download both from App Store and Play Store. It is intended to record patient responses to medical questionnaires which the patient is required to complete as part of their treatment. The Treating Practitioner will be able to view the responses to the medical questionnaires that the patients record in the App thereby allowing them to monitor the treatment in real time. The App will make it easy for the Treating Practitioners and MGC Pharma to evaluate and report the efficacy of CannEpil®.

Login

null null

The International Library of Cannabinoids (ILC)

The International Library of Cannabinoids (ILC) is a web-based application that provides an integrated and open source platform for cannabinoid research/user data from academia, industry and clinicians. The vision is that all cannabinoid research/user data will be deposited in a common repository and overtime this repository will provide evidence for efficacy of cannabinoid treatment of various disorders, and help doctors, researchers and industry to choose the right cannabinoid profiles for various conditions.
International Library of Cannabinoids

Webinars

An introduction to the Endocannabinoid System – Pharmaceutical Society of Australia February 2018. Presented by Justin Sinclair Research Fellow, NCIM (Western Sydney University)

Medical Cannabis for Australian Pharmacists PSA Webinar. Presented by Paul Mavor B.Pharm

Cannabidiol (CBD) in Refractory Epilepsy. Presented by Professor Uri Kramer
ASX: MXC
$0.059
Monday, 20 September 2021
Latest Announcements
16/9/21ARTEMIC EU SALE APPROVAL AND CLINICAL TRIAL UPDATE 14/9/21UK IMPORT PERMIT GRANTED FOR CANNEPIL 10/9/21Update - Notification of cessation of securities - MXC 10/9/21Update - Application for quotation of securities - MXC 9/9/21s708(5)(e) Cleansing Notice 9/9/21Appendix 3Y x 6 9/9/21Notification regarding unquoted securities - MXC

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
UK
European Corporate Headquarters
Who
What
Why
Contact Us